Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for quarter ended September 30, 2026 announced.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Press release issued October 28, 2026, with results in Exhibit 99.1
- Investor focus: quarterly performance details, guidance and outlook contained in the exhibit
Item 7.01 · Regulation FD Disclosure
- Quarterly Summary covers Glaukos’ third quarter ended September 30, 2026
- Supplemental business and financial information available in Exhibit 99.2
- Investor relevance: additional quarterly operating detail beyond the core 8-K disclosure
Item EX-99.1 · Exhibit EX-99.1
- Q3 net sales $211.0M, up 58%, led by Corneal Health growth of 154% and U.S. Glaucoma growth of 47%
- Gross margin expanded to 85.2% from 78.4%, supporting GAAP operating income of $0.8M versus a $16.4M loss
- GAAP net income $2.0M, or $0.03 diluted EPS, versus a $16.2M loss, though non-GAAP results exclude $26.5M of adjustments
- Cash, investments and restricted cash rose to $339.8M, with no debt, strengthening funding capacity for growth and development
- 2026 sales guidance raised to $775M-$785M, while preliminary 2027 guidance of $1B signals continued iDose TR and Epioxa momentum
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $211.0M, up 58%, with iDose TR sales approximately $76M and Epioxa sales approximately $53M
- Non-GAAP operating income $27.3M versus $9.3M loss, signaling operating leverage despite higher commercial and R&D investment
- FY2026 revenue guidance raised to $775-$785M from $680-$700M, reflecting accelerating iDose TR and Epioxa commercialization
- Preliminary FY2027 revenue guidance of $1B, establishing a high-growth target dependent on continued product adoption and reimbursement execution
- Cash, investments and restricted cash $339.8M, up $50.5M sequentially, strengthening funding for launches and pipeline development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.